Development and clinical validation of a quantitative mass spectrometric assay for PD-L1 protein in FFPE NSCLC samples

被引：0
|
作者：
An, E. [1 ]
Liao, W. [1 ]
Thyparambil, S. [1 ]
Rodriguez, J. [2 ]
Salgia, R. [3 ]
Wistuba, I. [2 ]
Burrows, J. [1 ]
Hembrough, T. [1 ]
机构：
[1] OncoPlex Diagnost, Rockville, MD USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Univ Chicago, Chicago, IL 60637 USA
来源：
EUROPEAN JOURNAL OF CANCER | 2014年 / 50卷
关键词：
D O I：
10.1016/S0959-8049(14)70615-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
489
引用
收藏
页码：159 / 159
页数：1
相关论文
共 50 条
  • [1] Development and clinical validation of a quantitative mass spectrometric assay for PD-L1 protein in FFPE NSCLC samples.
    An, Eunkyung
    Liao, Wei-Li
    Thyparambil, Sheeno
    Rodriguez, Jaime
    Salgia, Ravi
    Wistuba, Ignacio I.
    Burrows, Jon
    Hembrough, Todd
    CLINICAL CANCER RESEARCH, 2014, 20
  • [2] Development and clinical validation of a quantitative mass spectrometric assay for immuno-oncology targets in FFPE samples
    Thyparambil, Sheeno P.
    Cecchi, Fabiola
    An, Eunkyung
    Liao, Wei-Li
    Burrows, Jon
    Hembrough, Todd
    Catenacci, Daniel
    CANCER RESEARCH, 2015, 75
  • [3] Development and validation of an AI-based PD-L1 scoring algorithm in NSCLC samples
    Rodrigues, Daniela
    Neppl, Christina
    Dorward, David
    Losmanova, Tereza
    Wyatt, Rebecca
    Pattle, Samuel
    Oberson, Raphael
    Reinhard, Stefan
    Waldburger, Therese
    Zlobec, Inti
    Caie, Peter
    CANCER RESEARCH, 2023, 83 (07)
  • [4] Development of a sensitive and quantitative PD-L1 immunoassay superior to IHC with application in human FFPE tissue samples
    Wallweber, Gerald
    Chenna, Ahmed
    Ravanera, Roy
    Stathas, David
    Huang, Weidong
    Petropoulos, Christos
    CANCER RESEARCH, 2015, 75
  • [5] PD-L1 (SP263) staining of fine needle aspirate FFPE samples in NSCLC
    Hayden, D.
    Roland, B.
    Saufkie, K.
    Largo, S.
    Ahmadi, P.
    Vasquez, M.
    Newell, A. E. Hanlon
    Schnittker, K.
    ANNALS OF ONCOLOGY, 2020, 31 : S1113 - S1113
  • [6] Validation of VENTANA (SP263) PD-L1 immunohistochemistry (IHC) assay in formalin-fixed, paraffin embedded (FFPE) cytology samples
    Barker, C.
    Horne, H.
    Scorer, P.
    Roland, B.
    Hayden, D.
    Schnittker, K.
    VIRCHOWS ARCHIV, 2021, 479 : S158 - S159
  • [7] Clinical significance of inter-assay discrepancy in PD-L1 evaluation for the efficacy of pembrolizumab in advanced NSCLC with high PD-L1 expression
    Miyakoshi, Jun
    Yoshida, Tatsuya
    Kashima, Jumpei
    Shirasawa, Masayuki
    Torasawa, Masahiro
    Matsumoto, Yuji
    Masuda, Ken
    Shinno, Yuki
    Okuma, Yusuke
    Goto, Yasushi
    Horinouchi, Hidehito
    Shiraishi, Kouya
    Kohno, Takashi
    Yamamoto, Noboru
    Yatabe, Yasushi
    Suzuki, Takuji
    Ohe, Yuichiro
    LUNG CANCER, 2024, 191
  • [8] Comparison of PD-L1 mRNA expression measured with the CheckPointTyper® assay with PD-L1 protein expression assessed with immunohistochemistry (IHC) in lung cancer (NSCLC)
    Erber, R.
    Stoehr, R.
    Herlein, S.
    Fuchs, F.
    Veltrup, E.
    Wirtz, R.
    Hartmann, A.
    VIRCHOWS ARCHIV, 2017, 471 : S102 - S102
  • [9] Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics
    Zhang, Jie
    Gao, Jing
    Li, Yanyan
    Nie, Jun
    Dai, Ling
    Hu, Weiheng
    Chen, Xiaoling
    Han, Jindi
    Ma, Xiangjuan
    Tian, Guangming
    Wu, Di
    Shen, Lin
    Fang, Jian
    THORACIC CANCER, 2015, 6 (04) : 534 - 538
  • [10] PD-L1 Testing On NSCLC Cytology Samples in a UK Teaching Hospital
    Al-Najjar, H.
    Nadira, N.
    Higgins, C.
    Thiryayi, S.
    Shelton, D.
    Bailey, S.
    Rana, D.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S549 - S550
12345